title: Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
abstract: BACKGROUND
  Previous exposure to hypercortisolism due to Cushing's disease (CD) may adversely affect long-term metabolic and cardiovascular outcomes. In particular, metabolic and cardiovascular outcomes of patients with previous CD who require GH replacement have not been fully established.
  
  
  OBJECTIVE
  The aim of the study was to compare the prevalence and incidence of metabolic syndrome (Adult Treatment Panel III criteria), diabetes mellitus, cardiovascular disease, and cerebrovascular disease in GH-treated subjects with previous CD with GH-treated subjects with previous nonfunctioning pituitary adenoma (NFPA).
  
  
  METHODS
  We conducted post hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 362 international centers (1995-2006).
  
  
  METHODS
  We studied adult-onset GH-deficient subjects with previous CD (n = 160) or NFPA (n = 879). All subjects received GH replacement therapy and were GH naive at enrollment. Multiple pituitary deficits were prevalent in both groups.
  
  
  METHODS
  We measured the prevalence and incidence of metabolic syndrome, diabetes mellitus, cardiovascular disease, and cerebrovascular disease at baseline and at 3 yr, standardized for age and sex differences between groups.
  
  
  RESULTS
  Compared with subjects with previous NFPA, subjects with previous CD had a significantly greater 3-yr incidence of metabolic syndrome (CD, 23.4%; NFPA, 9.2%; P = 0.01), baseline (CD, 6.3%; NFPA, 2.2%; P < 0.01) and 3-yr (CD, 7.6%; NFPA, 3.9%; P = 0.04) prevalence of cardiovascular disease, and baseline (CD, 6.4%; NFPA, 1.8%; P = 0.03) and 3-yr (CD, 10.2%; NFPA, 2.9%; P = 0.01) prevalence of cerebrovascular disease.
  
  
  CONCLUSIONS
  Previous hypercortisolism may predispose GH-treated, GH-deficient subjects with prior CD to an increased risk of metabolic syndrome, cardiovascular disease, and cerebrovascular disease.
authors.affiliation: Department of Endocrinology, Hospital Sant Pau, Pare Claret 167, 08025 Barcelona, Spain. swebb@santpau.cat
authors.forename: Susan M
authors.initials: SM
authors.lastname: Webb
authors.forename: Daojun
authors.initials: D
authors.lastname: Mo
authors.forename: Steven W J
authors.initials: SW
authors.lastname: Lamberts
authors.forename: Shlomo
authors.initials: S
authors.lastname: Melmed
authors.forename: Francesco
authors.initials: F
authors.lastname: Cavagnini
authors.forename: Francesca
authors.initials: F
authors.lastname: Pecori Giraldi
authors.forename: Christian J
authors.initials: CJ
authors.lastname: Strasburger
authors.forename: Alan G
authors.initials: AG
authors.lastname: Zimmermann
authors.forename: Whitney W
authors.initials: WW
authors.lastname: Woodmansee
mesh_terms: D000236:Adenoma / Q000150:complications*; D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D002561:Cerebrovascular Disorders / Q000453:epidemiology*; D005260:Female; D019382:Human Growth Hormone / Q000172:deficiency*; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology*; D008875:Middle Aged; D047748:Pituitary ACTH Hypersecretion / Q000150:complications*; D010911:Pituitary Neoplasms / Q000150:complications*; D015995:Prevalence
chemical_list: D019382:Human Growth Hormone